These findings, together with ours, suggested that combined PlGF and VEGF inhibition may have a preferable benefit than simply targeting VEGF, particularly in disorders like diabetic retinopathy where inflammation becomes increasingly activated during the disease process. This evidence concerns the gene PGF and diabetic retinopathy.